In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lytix Biopharma AS

Latest From Lytix Biopharma AS

Verrica’s Anticancer Efforts Kick Off With Promising Early Phase II BCC Data

The US firm’s oncolytic peptide candidate, VP-315, has shown tumor clearance in a Phase II basal cell carcinoma trial, marking a positive start for its plans to expand from non-malignant dermatology to skin cancer.

Clinical Trials Cancer

Pipeline Watch: Phase III Progress With Nimotuzumab, Solriamfetol, And Upadacitinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Research & Development

Appointments: Sanofi, MSD, Pandion, Orchard, Redx, Glythera, Inotrem

Companies filling positions include Sanofi, with a new head of business transformation, and MSD Research Laboratories, with a leader for its new London early discovery facility. There is new leadership for Pandion Therapeutics, and further C-suite appointments at Orchard Therapeutics, Redx Pharma, Glythera and Inotrem.

Executive Changes Leadership

Pharmasum Therapeutics AS

Most individuals with Down syndrome who live long enough will develop Alzheimer’s disease, and Pharmasum Therapeutics AS hopes to develop an AD program by targeting a protein kinase that may underlie that association. The company intends to develop agents to treat AD in individuals with DS, a large and growing market, and potentially all other patients afflicted with Alzheimer’s.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Lytix Amicoat